An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2019
At a glance
- Drugs IONIS ANGPTL3 LRx (Primary)
- Indications Hypertriglyceridaemia; Lipodystrophy
- Focus Therapeutic Use
- Sponsors Akcea Therapeutics
- 16 Jan 2019 Planned End Date changed from 30 Apr 2019 to 30 Aug 2019.
- 16 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 30 Apr 2019.
- 16 Jan 2019 Status changed from recruiting to active, no longer recruiting.